{"slideshow_credits": null, "snippet": "Valeant said it had named three new directors to its board, including an executive from a major shareholder, Pershing Square Capital Management.", "abstract": "Valeant Pharmaceuticals, which is under scrutiny for its drug-pricing practices, says it is adding three new members to its board, including one from shareholder Pershing Square Capital Management; stock rises.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS"}, "web_url": "http://www.nytimes.com/2016/03/10/business/valeant-pharmaceuticals-adds-board-members.html", "lead_paragraph": "Valeant said it had named three new directors to its board, including an executive from a major shareholder, Pershing Square Capital Management.", "headline": {"main": "Valeant Pharmaceuticals Adds Board Members", "print_headline": "Valeant Takes Step to Soothe Investors"}, "_id": "56e0328d38f0d836dc036bd2", "word_count": "434", "multimedia": [{"height": 126, "url": "images/2016/03/10/business/10valeant-web1/10valeant-web1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/03/10/business/10valeant-web1/10valeant-web1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2016/03/10/business/10valeant-web1/10valeant-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/10/business/10valeant-web1/10valeant-web1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/03/10/business/10valeant-web1/10valeant-web1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/10/business/10valeant-web1/10valeant-web1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-03-10T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Pershing Square Capital Management", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Boards of Directors", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Appointments and Executive Changes", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}